Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

Anna Marie Wagner – Senior Vice President-Corporate Development

Jason Kelly – Co-Founder and Chief Executive Officer

Mark Dmytruk – Chief Financial Officer

Conference Call Participants

Matt Sykes – Goldman Sachs

Matt Larew – William Blair

Tejas Savant – Morgan Stanley

Steve Mah – Cowen

Rahul Sarugaser – Raymond James

Vivian Bais – BTIG

Anna Marie Wagner

Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. We thank you for joining us, and we look forward to providing you with an updating on our last quarter.

As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties. We'll follow our standard agenda for these calls, providing an update on our financial progress, while also taking time to dig deeper on our strategic priorities. We’ll end with a Q&A Session and I’ll take questions from analysts, investors and the public. As usual you can submit those questions to us in advance via Twitter, #GinkgoResults or e-mail at investors@ginkgobioworks.com.

All right, over to you Jason.

Jason Kelly

Thanks, Anna Marie. So we always start with this slide because our mission drives much of our long term strategy and even many day-to-day decisions here at Ginkgo. Very simply we want to make biology easier to engineer and we do that by scaling our platform for programming cells. I like this slide here as a summary of sort of the way our business works at Ginkgo. So our customers bring us ideas for what they want our cell to do. And we use our platform to engineer a cell that meets the customer specification. Our platform consists of two pieces, our Foundry and our Codebase. Our Foundry is an automated lab. I'm sitting here in Boston in a lab today and we believe the key value proposition for our customers is that we're able to turn what's typically an underutilized fixed cost investment for most companies, in other words, sort of a physical R&D lab in their facility, we can turn that into a highly efficient variable cost for them. And we can invest at Ginkgo in large scale infrastructure so that our customers can benefit from the scale economics we generate by having sort of one set of infrastructure serving many customers, instead of just scaled for one.